The availability of direct oral anticoagulants (DOAC s) has led to a paradigm shift in the field
of anticoagulation, with DOAC s increasingly being prescribed for patients in preference to …

Direct oral anticoagulants (DOACs) are increasingly used in the treatment and prophylaxis
of thromboembolism because of several advantages over vitamin K antagonists, including …

Background We elucidated the safety of treatment with alteplase at 0.6 mg/kg within 24
hours for patients on direct oral anticoagulants (DOACs) before ischemic stroke onset …

Background There is an increasing amount of literature on direct oral anticoagulant (DOAC)
laboratory monitoring. The aims of the present review were to evaluate published data on …

Background: Practice-based investigations on direct oral anticoagulant (DOAC) treatment for
non-valvular atrial fibrillation (NVAF) have shown that off-label under-dosing is increasingly …

Patients with atrial fibrillation (AF) on long-term direct oral anticoagulants (DOACs) may be
at higher risk of bleeding because of higher anti-Xa or anti-IIa levels. However, there is no …

Background: The rivaroxaban dose regimen for patients with nonvalvular atrial fibrillation
(NVAF) is complex in Asia. Given the high interindividual variability and the risk of bleeding …

Background The antithrombotic effect of direct oral anticoagulants (DOAC) in specific clinical
scenarios is difficult to assess. Objective This study aimed to evaluate the effect of DOAC on …

Background Rivaroxaban is an oral anticoagulant widely used for stroke prevention in
patients with non-valvular atrial fibrillation (NVAF). During long-term anticoagulant therapy …

Introduction Individual variability of rivaroxaban was observed in clinical application. This
study aimed to identify genetic variants associated with the variability of pharmacodynamics …